Argenta Discovery Ltd. has announced that it has entered into a fee-for-service collaboration with Antisoma plc. Under the terms of the agreement, scientists from the two organizations will work together to develop improved molecules for Antisoma’s programme of telomere targeting agents (TTAs).
Antisoma will utilise Argenta’s expertise in medicinal chemistry, computer-aided drug design, molecular biology, biochemistry, assay development and in vitro screening, during the course of the collaboration.
Commenting on the agreement, Dr Christopher Ashton, Argenta’s Chief Executive, said, “We are pleased that Antisoma has chosen to collaborate with Argenta on this project. Antisoma’s decision to work with us confirms our contract research team’s experience in undertaking integrated, oncology-focused programmes, and underlines Argenta’s on-going commitment to providing first class contract R & D services to leading organisations in the pharmaceutical industry. We look forward to building a long-term scientific and business relationship with Antisoma.”
Dr Fiona McLaughlin, Director of Research at Antisoma said, "We are looking forward to working with Argenta on the TTA project. This is part of our effort to add new candidates to the promising tumour-targeting therapeutics we already have in the clinic. Argenta is well-known and respected within the pharmaceutical industry for its high-quality medicinal chemistry services, and was therefore a natural choice as partner for this work.”
Financial terms of the deal were not disclosed, but the agreement does provide options to expand the relationship.